New quarterly report expected Apr 22, 2026. Report will refresh after results.
C
CME Group Inc.
CME · Financial Services
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 15, 2026
The World's Best Toll Road, Priced Like It
Most investors underestimate two things simultaneously: how durable the moat truly is (decades of entrenched institutional workflow, not just network effects), and how dependent the earnings power is on a single macro variable — rate volatility — that CME neither controls nor can fully hedge. The SOFR transition and the potential SEC treasury clearing mandate are compounding tailwinds hiding in plain sight, but they only matter if the underlying vol regime cooperates.
Flowly Score
Apr 16 Close
+5%$296.22
Fair Value
$310.00
74
Strongat $296.22
Business Strength9/10
A genuine liquidity monopoly protected by self-reinforcing network effects, contractual index exclusivity, and switching costs baked into the compliance infrastructure of every major bank on earth — the moat compounds rather than merely persists. The only honest knock is that management has limited high-return reinvestment opportunities, making this a superb earner that routes most of its earnings out the door rather than a classic internal compounder.
Financial Resilience8/10
Operating cash flow running ahead of reported earnings across most of the cycle is the fingerprint of genuine earnings quality, and CapEx so small it barely registers makes this one of the most capital-light businesses in financial services. The Piotroski at 4 flags operational softness worth watching, and the Altman Z is distorted by clearing house collateral bloating the balance sheet — not a solvency signal, but a reminder that the numbers require interpretation.
Growth & Trajectory7/10
Five consecutive record years is not luck — it reflects operating leverage compounding on top of a structurally elevated volatility regime, and management is stacking new growth vectors (crypto 24/7, event contracts, securities clearing mandate) on top of the core franchise before the old ones mature. The honest constraint is that this is a mid-single-digit revenue grower at best, with earnings acceleration coming from margin expansion that has its own ceiling.
Valuation6/10at $311.40
At current multiples, the market is pricing in exactly what CME has delivered — steady compounding with no re-rating — which means you're buying a superb business at a fair price, not a great business at a cheap one. The gap between the current price and the fair value estimate is narrow enough to be inside the error bars of any reasonable DCF, leaving no margin of safety for a scenario where rate volatility reverts.
Risk7/10
The moat is genuinely one of the strongest in financial services, which keeps the risk score from dipping lower — you cannot simply out-technology a century of accumulated liquidity. The concentration in interest rate futures introduces meaningful cyclicality, the index licensing agreements represent a structural dependency on third-party goodwill, and DeFi perpetual infrastructure is a slow-moving counter-positioning threat that deserves more respect than the market gives it.
CME is the rare business where the quality case is almost impossible to argue with and the price case is almost impossible to get excited about — those two things coexist here in an unusual equilibrium. The toll-road analogy understates the moat: this isn't a road where you can theoretically build a parallel one, it's a road where the value of the road is defined by how many cars are already on it, which makes the incumbent position self-reinforcing in ways that decade-long competitors have repeatedly failed to dislodge. At current multiples, the market has figured this out and priced in continuation — which is a defensible outcome, not a compelling entry. The trajectory is more interesting than the steady-compounder narrative suggests. Market data has now grown for 31 consecutive quarters — a recurring revenue stream quietly growing into a meaningful offset to volume cyclicality. Crypto futures volume tripling in a quarter and event contracts generating tens of millions of trades in their first six weeks are not noise; they are early signals of CME successfully colonizing new asset classes before those markets mature enough for competitors to anchor. The cross-margining efficiency story — where CME's breadth of cleared products generates margin savings that competitors structurally cannot replicate — is the clearest evidence that the moat is actively widening, not coasting. The single biggest risk, named specifically: a sustained return to a low-rate, low-volatility macro regime. The years when central banks telegraphed every move and rates were structurally anchored near zero showed exactly what happens to CME's core revenue engine — it idles. No crypto futures franchise, no event contracts launch, and no market data subscription business can fully replace the volume that disappears when the rate market goes to sleep. The bull case implicitly assumes that the post-2022 volatility regime is the new normal; if it isn't, the current earnings base overstates normalized earnings power in ways the multiple does not yet reflect.